New FDA Conflict Of Interest Policy Enacted At MT 100 Committee Meeting

FDA's new conflict-of-interest disclosure policy for advisory committee members was inaugurated at the Aug. 4 Peripheral & Central Nervous System Drugs Advisory Committee meeting